Genetic testing for diagnosis and management of mental health disorders is considered investigational in all situations, including but not limited to the following:
To confirm a diagnosis of a mental health disorder in an individual with symptoms.
To predict future risk of a mental health disorder in an asymptomatic individual.
To inform the selection or dose of medications used to treat mental health disorders, including but not limited to the following medications:
selective serotonin reuptake inhibitors
selective norepinephrine reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors
tricyclic antidepressants
antipsychotic drugs.
Genetic testing panels for mental health disorders, including but not limited to the Genecept Assay, STA2R test, the GeneSight Psychotropic panel, the Proove Opioid Risk assay, and the Mental Health DNA Insight panel, are considered investigational for all indications.
